Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, Lung-Yi | - |
dc.contributor.author | Hoang, Joseph | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Chen, Chien-Hung | - |
dc.contributor.author | Peng, Cheng-Yuan | - |
dc.contributor.author | Yeh, Ming-Lun | - |
dc.contributor.author | Kim, Sung Eun | - |
dc.contributor.author | Huang, Daniel Q. | - |
dc.contributor.author | Jeong, Jae Yoon | - |
dc.contributor.author | Yoon, Eileen | - |
dc.contributor.author | Oh, Hyunwoo | - |
dc.contributor.author | Tsai, Pei-Chien | - |
dc.contributor.author | Huang, Chung-Feng | - |
dc.contributor.author | Ahn, Sang Bong | - |
dc.contributor.author | Trinh, Huy | - |
dc.contributor.author | Xie, Qing | - |
dc.contributor.author | Wong, Grace L. H. | - |
dc.contributor.author | Enomoto, Masaru | - |
dc.contributor.author | Shim, Jae-Jun | - |
dc.contributor.author | Lee, Dong-Hyun | - |
dc.contributor.author | Liu, Li | - |
dc.contributor.author | Kozuka, Ritsuzo | - |
dc.contributor.author | Cho, Yong Kyun | - |
dc.contributor.author | Jeong, Soung Won | - |
dc.contributor.author | Kim, Hyoung Su | - |
dc.contributor.author | Trinh, Lindsey | - |
dc.contributor.author | Dao, Allen | - |
dc.contributor.author | Huang, Rui | - |
dc.contributor.author | Hui, Rex Wan-Hin | - |
dc.contributor.author | Tsui, Vivien | - |
dc.contributor.author | Quek, Sabrina | - |
dc.contributor.author | Khine, Htet Htet Toe Wai | - |
dc.contributor.author | Ogawa, Eiichi | - |
dc.contributor.author | Dai, Chia Yen | - |
dc.contributor.author | Huang, Jee Fu | - |
dc.contributor.author | Cheung, Ramsey | - |
dc.contributor.author | Wu, Chao | - |
dc.contributor.author | Chuang, Wan-Long | - |
dc.contributor.author | Lim, Seng Gee | - |
dc.contributor.author | Yu, Ming-Lung | - |
dc.contributor.author | Yuen, Man-Fung | - |
dc.contributor.author | Nguyen, Mindie H. | - |
dc.date.accessioned | 2022-07-06T10:29:58Z | - |
dc.date.available | 2022-07-06T10:29:58Z | - |
dc.date.created | 2021-12-08 | - |
dc.date.issued | 2022-02 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/139670 | - |
dc.description.abstract | Background and aims We aimed to compare the longitudinal changes in estimated glomerular filtration rate (eGFR) in chronic hepatitis B (CHB) patients treated with entecavir (ETV) vs. tenofovir disoproxil fumarate (TDF). Methods This is a retrospective study of 6189 adult treatment-naïve CHB patients initiated therapy with TDF (n = 2482) or ETV (n = 3707) at 25 international centers using multivariable generalized linear modeling (GLM) to determine mean eGFR (mL/min/1.73 m2) and Kaplan–Meier method to estimate incidence of renal impairment (≥ 1 chronic kidney disease [CKD] stage worsening). We also examined above renal changes in matched ETV and TDF patients (via propensity score matching [PSM] on age, sex, diabetes mellitus [DM], hypertension [HTN], cirrhosis, baseline eGFR, and follow-up duration). Results In the overall cohort (mean age 49.7 years, 66.2% male), the baseline eGFR was higher for TDF vs. ETV group (75.9 vs. 74.0, p = 0.009). PSM yielded 1871 pairs of ETV or TDF patients with baseline eGFR ≥ 60 and 520 pairs for the eGFR < 60 group. GLM analysis of the overall (unmatched) cohort and PSM cohorts revealed lower adjusted mean eGFRs in TDF (vs. ETV) patients (all p < 0.01) during 10 years of follow-up. Among PSM eGFR ≥ 60 patients, the 5-year cumulative incidences of renal impairment were 42.64% for ETV and 48.03% for TDF (p = 0.0023). In multivariable Cox regression, TDF vs. ETV (adjusted HR 1.26, 95% CI 1.11–1.43) was associated with higher risk of worsening renal function. Conclusion Over the 10-year study follow-up, compared to ETV, TDF was associated with a lower mean eGFR and higher incidence of renal impairment. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.title | Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jun, Dae Won | - |
dc.identifier.doi | 10.1007/s12072-021-10271-x | - |
dc.identifier.scopusid | 2-s2.0-85119872419 | - |
dc.identifier.wosid | 000722481000002 | - |
dc.identifier.bibliographicCitation | HEPATOLOGY INTERNATIONAL, v.16, no.1, pp.48 - 58 | - |
dc.relation.isPartOf | HEPATOLOGY INTERNATIONAL | - |
dc.citation.title | HEPATOLOGY INTERNATIONAL | - |
dc.citation.volume | 16 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 48 | - |
dc.citation.endPage | 58 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Early Access | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | CHRONIC KIDNEY-DISEASE | - |
dc.subject.keywordPlus | POLYMERASE INHIBITORS | - |
dc.subject.keywordPlus | TENOFOVIR ALAFENAMIDE | - |
dc.subject.keywordPlus | NUCLEOS(T)IDE ANALOGS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | FUMARATE | - |
dc.subject.keywordPlus | COHORT | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordAuthor | Real-world study | - |
dc.subject.keywordAuthor | Renal function | - |
dc.subject.keywordAuthor | Chronic kidney disease | - |
dc.subject.keywordAuthor | Long-term follow-up | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s12072-021-10271-x | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.